Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
1. NBIX reported better-than-expected Q1 2025 earnings but lower EPS than last year. 2. Sales rose to $572.6 million, missing the consensus of $559.3 million. 3. Ingrezza sales grew 8%, exceeding expectations despite competitive pressures. 4. Analysts maintain 'Buy' ratings, raising price targets for NBIX stock. 5. Stock increased by 14% following the earnings report.